Guardant Health and Policlinico Gemelli Announce Partnership to Establish A Dedicated In-House Liquid Biopsy Testing Service in Italy
10 Septiembre 2024 - 7:00AM
Business Wire
Leading Italian Hospital System To Offer
Proprietary Guardant360® CDx Liquid Biopsy Testing for
Therapy Selection in Advanced Cancer Patients
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology
company, today announced a partnership with the Agostino Gemelli
University Polyclinic Foundation IRCCS (“Policlinico Gemelli”) to
establish an in-house liquid biopsy testing service as a part of
its diagnostics services within its hospital system. Leveraging
Guardant Health’s cutting-edge proprietary digital sequencing
platform, this initiative will include on-site analysis of
Guardant360® CDx liquid biopsy tests directly within the
Policlinico Gemelli facilities in Rome, Italy.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20240910971779/en/
The partnership will serve clinical research and patient care
needs, marking a significant milestone as one of the first
dedicated liquid biopsy testing facilities in Italy housed within a
hospital system. This collaboration underscores Guardant Health’s
commitment to expanding access to innovative cancer diagnostics and
improving patient outcomes globally. Policlinico Gemelli, one of
Italy’s largest and most renowned hospitals, serves thousands of
cancer patients each year at its comprehensive cancer center. The
facility is known for its advanced oncology services, including
diagnostics, treatment, and research.
“Gemelli, one of the most important Italian and European
oncology centers, can now offer its patients more state-of-the-art
diagnostics for precision oncology through this innovative test.
This partnership with Guardant Health represents a fundamental step
for our hospital,” said Professor Giovanni Scambia, Scientific
Director of Policlinico Gemelli.
In Italy, approximately 400,000 new malignant tumor cases are
recorded annually. The average of annual deaths caused by tumors,
according to the Italian Cancer Registers, is about 3.5 deaths and
about 2.5 per 1,000 men and women, respectively, for a total of
about three deaths every 1,000 people.1 Guardant Health’s tests are
used by oncologists worldwide to guide treatment decisions across
solid tumor cancers and by pharmaceutical companies and academic
researchers in clinical trials to accelerate precision medicine
drug development.
In 2024, Guardant Health announced certification for its
Guardant360® CDx blood test under the European Union’s In Vitro
Diagnostic Regulation (IVDR 2017/746). The certification from TÜV
SÜD Product Service is for tumor mutation profiling in patients
with any solid cancerous tumor and for companion diagnostic
indications to identify patients who may benefit from certain
targeted therapies for advanced non-small cell lung cancer and
breast cancer.
“We’re thrilled to partner with Policlinico Gemelli, empowering
clinicians to swiftly detect tumor alterations with a blood test,
guiding personalized treatments, and fueling research innovation.
This collaboration brings us closer to our mission of ensuring all
cancer patients worldwide have access to the latest advancements
for optimal care,” said Helmy Eltoukhy, Guardant Health Co-CEO.
About Guardant Health
Guardant Health is a leading precision oncology company focused
on guarding wellness and giving every person more time free from
cancer. Founded in 2012, Guardant is transforming patient care by
providing critical insights into what drives disease through its
advanced blood and tissue tests, real-world data and AI analytics.
Guardant tests help improve outcomes across all stages of care,
including screening to find cancer early, monitoring for recurrence
in early-stage cancer, and helping doctors select the best
treatment for patients with advanced cancer. For more information,
visit guardanthealth.com and follow the company on LinkedIn, X
(Twitter) and Facebook.
About Policlinico Gemelli
Policlinico Universitario Agostino Gemelli IRCCS was founded in
July 1964 by the will of Istituto Toniolo di Studi Superiori e
Università Cattolica del Sacro Cuore. Home to the Faculty of
Medicine and Surgery, it is one of the largest non-state hospitals
in Europe and a place where teaching, innovative research, care and
assistance activities dialogue. Since August 2015, it has assumed
the legal form of a Foundation and, since 2018, the qualification
of a Scientific Institute for Hospitalization and Care (IRCCS) for
the disciplines of Personalised Medicine and Innovative
Biotechnology. Today, Gemelli is also the largest oncology hospital
in Italy, with over 50,000 patients treated on average every year,
and one of the most important research and assistance centers in
Europe. In June 2021, Policlinico Gemelli obtained the
accreditation of the Joint Commission International (JCI), one of
the largest and most prestigious certification bodies in the world,
confirmed for another three years. Furthermore, Gemelli is the best
hospital in Italy and 35th in the world according to the World’s
Best Hospital 2024 ranking by "Newsweek," in collaboration with
Statista Inc.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of federal securities laws, including statements
regarding the potential utilities, values, benefits and advantages
of Guardant Health’s liquid biopsy tests or assays, which involve
risks and uncertainties that could cause the actual results to
differ materially from the anticipated results and expectations
expressed in these forward-looking statements. These statements are
based on current expectations, forecasts and assumptions, and
actual outcomes and results could differ materially from these
statements due to a number of factors. These and additional risks
and uncertainties that could affect Guardant Health’s financial and
operating results and cause actual results to differ materially
from those indicated by the forward-looking statements made in this
press release include those discussed under the captions “Risk
Factors” and “Management’s Discussion and Analysis of Financial
Condition and Results of Operation” and elsewhere in its Annual
Report on Form 10-K for the year ended December 31, 2023, and any
current and periodic reports filed with or furnished to the
Securities and Exchange Commission thereafter. The forward-looking
statements in this press release are based on information available
to Guardant Health as of the date hereof, and Guardant Health
disclaims any obligation to update any forward-looking statements
provided to reflect any change in its expectations or any change in
events, conditions, or circumstances on which any such statement is
based, except as required by law. These forward-looking statements
should not be relied upon as representing Guardant Health’s views
as of any date subsequent to the date of this press release.
References
- Tonetti, C., Tonetti, C., Lombardo, F., Rizzo, F., & Lolli,
S. (2022). A review of hospital-based cancer registries in Italy.
Scientific Data.
https://www.nature.com/articles/s41597-022-01729-0
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240910971779/en/
Investor Contact: Zarak Khurshid
investors@guardanthealth.com
Media Contact: Guardant Health Melissa Marasco
press@guardanthealth.com +1 650-647-3711
Policlinico Gemelli Nicola Cerbino
nicola.cerbino@policlinicogemelli.it + 39 06 3015 4442
Guardant Health (NASDAQ:GH)
Gráfica de Acción Histórica
De Dic 2024 a Ene 2025
Guardant Health (NASDAQ:GH)
Gráfica de Acción Histórica
De Ene 2024 a Ene 2025
